Published in Lancet Neurol on April 29, 2010
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology (2012) 3.46
Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease. Parkinsonism Relat Disord (2014) 2.86
Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord (2016) 2.68
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology (2014) 2.10
Short pulse width widens the therapeutic window of subthalamic neurostimulation. Ann Clin Transl Neurol (2015) 1.86
What brain signals are suitable for feedback control of deep brain stimulation in Parkinson's disease? Ann N Y Acad Sci (2012) 1.31
Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harb Perspect Med (2012) 1.30
High frequency deep brain stimulation attenuates subthalamic and cortical rhythms in Parkinson's disease. Front Hum Neurosci (2012) 1.29
Parkinson’s disease DBS: what, when, who and why? The time has come to tailor DBS targets. Expert Rev Neurother (2010) 1.24
Deep brain stimulation for movement disorders. Front Integr Neurosci (2012) 1.24
Randomized controlled clinical trial of "virtual house calls" for Parkinson disease. JAMA Neurol (2013) 1.24
Effects of deep brain stimulation of the subthalamic nucleus on inhibitory and executive control over prepotent responses in Parkinson's disease. Front Syst Neurosci (2013) 1.22
Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry (2013) 1.20
Parkinson's disease dementia: a neural networks perspective. Brain (2015) 1.10
Parkinson disease: deep brain stimulation versus best medical therapy for PD. Nat Rev Neurol (2010) 1.08
Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making. Brain (2012) 1.07
Deep brain stimulation (DBS) at the interface of neurology and psychiatry. J Clin Invest (2013) 1.07
Closed-loop neurostimulation: the clinical experience. Neurotherapeutics (2014) 1.05
Acute and Chronic Mood and Apathy Outcomes from a randomized study of unilateral STN and GPi DBS. PLoS One (2014) 1.01
Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials. J Neurol (2014) 0.99
Understanding the impact of deep brain stimulation on ambulatory activity in advanced Parkinson's disease. J Neurol (2011) 0.99
Deep brain stimulation: technology at the cutting edge. J Clin Neurol (2010) 0.97
Late-stage Parkinson disease. Nat Rev Neurol (2012) 0.97
Mechanisms of deep brain stimulation. J Neurophysiol (2015) 0.93
Focusing brain therapeutic interventions in space and time for Parkinson's disease. Curr Biol (2014) 0.93
Review: management of Parkinson's disease. Neuropsychiatr Dis Treat (2013) 0.93
Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review. Front Neurol (2012) 0.92
Health-related quality of life as an outcome variable in Parkinson's disease. Ther Adv Neurol Disord (2012) 0.92
Site of deep brain stimulation and jaw velocity in Parkinson disease. J Neurosurg (2011) 0.91
STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice. Mov Disord Clin Pract (2014) 0.90
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol (2013) 0.90
Disparities in deep brain stimulation surgery among insured elders with Parkinson disease. Neurology (2013) 0.89
Surgical treatment of Parkinson's disease: patients, targets, devices, and approaches. Neurotherapeutics (2014) 0.89
Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord (2011) 0.88
Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. J Neurol Neurosurg Psychiatry (2014) 0.87
Optimal target localization for subthalamic stimulation in patients with Parkinson disease. Neurology (2014) 0.86
Industrial perspective on deep brain stimulation: history, current state, and future developments. Front Integr Neurosci (2011) 0.85
Current perspectives on deep brain stimulation for severe neurological and psychiatric disorders. Neuropsychiatr Dis Treat (2015) 0.85
Subthalamic nucleus long-range synchronization-an independent hallmark of human Parkinson's disease. Front Syst Neurosci (2013) 0.85
Treatment of advanced Parkinson's disease. Curr Opin Neurol (2014) 0.85
The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease. J Neurol (2013) 0.84
Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol (2013) 0.84
Deep brain stimulation. Interv Neurol (2013) 0.84
Novel applications of deep brain stimulation. Surg Neurol Int (2012) 0.83
Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials. Clin Interv Aging (2016) 0.83
Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Mov Disord (2015) 0.82
Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy? Ther Adv Neurol Disord (2012) 0.82
The treatment of Parkinson's disease with deep brain stimulation: current issues. Neural Regen Res (2015) 0.82
Movement disorders and neuromodulation. Neurol Res Int (2012) 0.82
Update on deep brain stimulation in Parkinson's disease. Transl Neurodegener (2015) 0.82
Perceptions of symptoms and expectations of advanced therapy for Parkinson's disease: preliminary report of a Patient-Reported Outcome tool for Advanced Parkinson's disease (PRO-APD). Health Qual Life Outcomes (2014) 0.82
Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation. Neurology (2014) 0.82
Impulsive and compulsive behaviors in Parkinson's disease. Front Aging Neurosci (2014) 0.82
Deep brain stimulation in Parkinson's disease. Transl Neurodegener (2013) 0.81
Spinal stimulation for movement disorders. Neurotherapeutics (2014) 0.81
Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple-treatments meta-analysas of randomized controlled trials. Sci Rep (2016) 0.79
Spinal cord stimulation for Parkinson's disease: a systematic review. Neurosurg Rev (2015) 0.79
Deep brain stimulation for movement disorders - a history of success and challenges to conquer. Front Integr Neurosci (2012) 0.79
Surgical treatment of Parkinson disease: past, present, and future. Neurol Clin (2013) 0.79
Movement disorders in 2010: Parkinson disease-symptoms and treatments. Nat Rev Neurol (2011) 0.79
Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety. Degener Neurol Neuromuscul Dis (2012) 0.79
Technological advances in the surgical treatment of movement disorders. Curr Neurol Neurosci Rep (2013) 0.79
Update on Deep Brain Stimulation for Dyskinesia and Dystonia: A Literature Review. Neurol Med Chir (Tokyo) (2016) 0.78
The impact of deep brain stimulation on the nonmotor symptoms of Parkinson's disease. J Neural Transm (Vienna) (2012) 0.78
Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis. PLoS One (2016) 0.78
Deep brain stimulation for advanced Parkinson's disease. Lancet Neurol (2010) 0.78
Long-term Efficacy of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A 5-year Follow-up Study in China. Chin Med J (Engl) (2015) 0.77
Adult human olfactory epithelial-derived progenitors: a potential autologous source for cell-based treatment for Parkinson's disease. Stem Cells Transl Med (2012) 0.77
Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease. Front Neurosci (2016) 0.77
Perspective on the economic evaluation of deep brain stimulation. Front Integr Neurosci (2011) 0.77
Coordinate-based lead location does not predict Parkinson's disease deep brain stimulation outcome. PLoS One (2014) 0.76
Deep Brain Stimulation in Neurological and Psychiatric Disorders. Dtsch Arztebl Int (2015) 0.76
Critical aspects of clinical trial design for novel cell and gene therapies. Parkinsons Dis (2011) 0.76
Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2016) 0.76
Subthalamic nucleus deep brain stimulation induces impulsive action when patients with Parkinson's disease act under speed pressure. Exp Brain Res (2016) 0.76
DBS amplitude setting can improve aspects of quality of life in patients with Parkinson's disease. J Neural Transm (Vienna) (2013) 0.76
Deep brain stimulation for Parkinson's disease: recent trends and future direction. Neurol Med Chir (Tokyo) (2015) 0.76
Design, Fabrication, Simulation and Characterization of a Novel Dual-Sided Microelectrode Array for Deep Brain Recording and Stimulation. Sensors (Basel) (2016) 0.76
Deep brain stimulation in Parkinson's disease: motor effects relative to the MRI-defined STN. Neurosurg Rev (2014) 0.76
Comparison of Bilateral vs. Staged Unilateral Deep Brain Stimulation (DBS) in Parkinson's Disease in Patients Under 70 Years of Age. Neuromodulation (2015) 0.75
Use of deep brain stimulation for major affective disorders. Exp Ther Med (2016) 0.75
Algorithmic design of a noise-resistant and efficient closed-loop deep brain stimulation system: A computational approach. PLoS One (2017) 0.75
A review of social and relational aspects of deep brain stimulation in Parkinson's disease informed by healthcare provider experiences. Parkinsons Dis (2011) 0.75
An update on the diagnosis and treatment of Parkinson disease. CMAJ (2016) 0.75
Deep brain stimulation and neuropsychology: a step forward? Nat Rev Neurol (2011) 0.75
Target Selection Recommendations Based on Impact of Deep Brain Stimulation Surgeries on Nonmotor Symptoms of Parkinson's Disease. Chin Med J (Engl) (2015) 0.75
Impact of bilateral subthalamic stimulation on motor/cognitive functions in Parkinson's disease. Neurol Med Chir (Tokyo) (2014) 0.75
The role of deep brain stimulation in Parkinson's disease: an overview and update on new developments. Neuropsychiatr Dis Treat (2017) 0.75
Impact of Combined Subthalamic Nucleus and Substantia Nigra Stimulation on Neuropsychiatric Symptoms in Parkinson's Disease Patients. Parkinsons Dis (2017) 0.75
Interventional magnetic resonance imaging-guided subthalamic nucleus deep brain stimulation for Parkinson's disease: Patient selection. Surg Neurol Int (2016) 0.75
Current Topics in Deep Brain Stimulation for Parkinson Disease. Neurol Med Chir (Tokyo) (2016) 0.75
Computational Modeling and Neuroimaging Techniques for Targeting during Deep Brain Stimulation. Front Neuroanat (2016) 0.75
Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options. P T (2015) 0.75
Interventional MR Imaging for Deep-Brain Stimulation Electrode Placement. Radiology (2016) 0.75
Feature visualization and classification for the discrimination between individuals with Parkinson's disease under levodopa and DBS treatments. Biomed Eng Online (2016) 0.75
Rescue Procedures after Suboptimal Deep Brain Stimulation Outcomes in Common Movement Disorders. Brain Sci (2016) 0.75
Deep brain stimulation of pallidal versus subthalamic for patients with Parkinson's disease: a meta-analysis of controlled clinical trials. Neuropsychiatr Dis Treat (2016) 0.75
My 25 Stimulating Years with DBS in Parkinson's Disease. J Parkinsons Dis (2017) 0.75
Parkinsonism: onset, progression and mortality. Neurology (1967) 36.06
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry (1988) 14.72
Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet (2000) 9.80
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA (2009) 8.40
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord (2003) 6.94
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med (1998) 4.72
Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science (1990) 3.74
The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing (1997) 3.71
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord (2006) 2.81
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta-analysis of ten years' experience. Mov Disord (2007) 2.47
Implantation of deep brain stimulators into the subthalamic nucleus: technical approach and magnetic resonance imaging-verified lead locations. J Neurosurg (2002) 2.25
Dopamine-dependent changes in the functional connectivity between basal ganglia and cerebral cortex in humans. Brain (2002) 2.15
Suicide after successful deep brain stimulation for movement disorders. Neurology (2004) 1.98
Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing (2001) 1.92
Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol (2006) 1.82
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Multicenter study on deep brain stimulation in Parkinson's disease: an independent assessment of reported adverse events at 4 years. Mov Disord (2008) 1.65
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience (1989) 1.64
Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord (1991) 1.62
Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.44
Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. J Neurosurg (2005) 1.42
Deep brain stimulation of the subthalamic nucleus: anatomical, neurophysiological, and outcome correlations with the effects of stimulation. J Neurol Neurosurg Psychiatry (2002) 1.40
Treatments for Parkinson disease--past achievements and current clinical needs. Neurology (2009) 1.25
Frequency-dependent reciprocal modulation of verbal fluency and motor functions in subthalamic deep brain stimulation. Arch Neurol (2006) 1.16
Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: an ECD-SPECT study. Parkinsonism Relat Disord (2007) 1.00
Methodology of neuropsychological research in multicentre randomized clinical trials: a model derived from the International Subarachnoid Aneurysm Trial. Clin Trials (2004) 0.92
Surgery for Parkinson's disease: lack of reliable clinical trial evidence. J Neurol Neurosurg Psychiatry (2003) 0.91
The Parkinson's Disease Questionnaire (PDQ-39): evidence for a method of imputing missing data. Age Ageing (2006) 0.85
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med (2009) 10.60
A comparison of whole-genome shotgun-derived mouse chromosome 16 and the human genome. Science (2002) 9.59
Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord (2010) 9.34
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol (2012) 5.52
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature (2007) 5.03
Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet (2002) 4.86
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol (2010) 4.12
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med (2005) 3.92
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet (2005) 3.75
European patients' views on the responsiveness of health systems and healthcare providers. Eur J Public Health (2005) 3.44
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol (2003) 2.80
Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol (2013) 2.74
Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet (2009) 2.59
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood (2008) 2.55
Levonorgestrel intrauterine system versus medical therapy for menorrhagia. N Engl J Med (2013) 2.50
The routine use of patient reported outcome measures in healthcare settings. BMJ (2010) 2.49
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol (2009) 2.43
Parkin disease: a phenotypic study of a large case series. Brain (2003) 2.41
The syndrome of fixed dystonia: an evaluation of 103 patients. Brain (2004) 2.36
Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord (2010) 2.36
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol (2009) 2.26
Accuracy of pulse oximetry in screening for congenital heart disease in asymptomatic newborns: a systematic review. Arch Dis Child Fetal Neonatal Ed (2007) 2.14
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev (2003) 2.08
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol (2009) 1.96
Hunger: its impact on children's health and mental health. Pediatrics (2002) 1.92
Microarray transcription analysis of clinical Staphylococcus aureus isolates resistant to vancomycin. J Bacteriol (2003) 1.92
PEPtalk: postexposure prophylaxis against varicella in children with cancer. Arch Dis Child (2011) 1.91
A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain (2011) 1.89
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood (2005) 1.85
High rates of clustering of strains causing tuberculosis in Harare, Zimbabwe: a molecular epidemiological study. J Clin Microbiol (2004) 1.84
Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev (2012) 1.80
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol (2007) 1.79
An exploration of social and economic outcome and associated health-related quality of life after critical illness in general intensive care unit survivors: a 12-month follow-up study. Crit Care (2013) 1.78
Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord (2005) 1.77
α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol (2013) 1.75
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol (2010) 1.70
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood (2005) 1.70
Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. Mov Disord (2004) 1.69
Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril (2011) 1.69
Management of respiration in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler (2006) 1.69
Progressive delayed-onset dystonia after cerebral anoxic insult in adults. Mov Disord (2002) 1.69
Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68
Measuring patients' experiences and outcomes. BMJ (2009) 1.65
A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol (2006) 1.61
Globus pallidus internus deep brain stimulation for dystonic conditions: a prospective audit. Mov Disord (2003) 1.58
Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial. Obstet Gynecol (2011) 1.57
A Review: carers, MND and service provision. Amyotroph Lateral Scler (2006) 1.55
PLUTO trial protocol: percutaneous shunting for lower urinary tract obstruction randomised controlled trial. BJOG (2007) 1.55
Noninvasive metabolomic profiling of embryo culture media using Raman and near-infrared spectroscopy correlates with reproductive potential of embryos in women undergoing in vitro fertilization. Fertil Steril (2007) 1.52
Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol (2013) 1.52
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol (2009) 1.52
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood (2007) 1.51
Developing symptom-based predictive models of endometriosis as a clinical screening tool: results from a multicenter study. Fertil Steril (2012) 1.50
Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol (2005) 1.50
Whole-genome sequencing of Staphylococcus aureus strain RN4220, a key laboratory strain used in virulence research, identifies mutations that affect not only virulence factors but also the fitness of the strain. J Bacteriol (2011) 1.48
Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain (2006) 1.48
Camptocormia treated with bilateral pallidal stimulation. J Neurosurg (2002) 1.45
Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord (2007) 1.44
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol (2011) 1.44
Dopaminergic modulation of striato-frontal connectivity during motor timing in Parkinson's disease. Brain (2010) 1.43
Influence of an artificial cervical joint compared with fusion on adjacent-level motion in the treatment of degenerative cervical disc disease. J Neurosurg (2002) 1.43
Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol (2011) 1.42
The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS (2002) 1.41
Health selection in the Whitehall II study, UK. Soc Sci Med (2003) 1.41
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol (2002) 1.40
Reprogramming of human somatic cells using human and animal oocytes. Cloning Stem Cells (2009) 1.40
"1858-1958"-Some Reflections on the Evolution of the Training of the Family Doctor. J Coll Gen Pract Res Newsl (1958) 1.40
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood (2013) 1.36
Physiotherapy intervention in Parkinson's disease: systematic review and meta-analysis. BMJ (2012) 1.35
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord (2010) 1.34
Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord (2003) 1.34
Health-related quality of life measurement in women with common benign gynecologic conditions: a systematic review. Am J Obstet Gynecol (2002) 1.23
Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant (2003) 1.23